カリフォルニア州における非小細胞肺癌の臨床試験
カリフォルニア州内の拠点で、非小細胞肺癌に関する207件の研究が参加者を募集しています。
カリフォルニア州内の都市
- Los Angeles87件の研究
- San Diego48件の研究
- Santa Monica45件の研究
- San Francisco36件の研究
- Baldwin Park36件の研究
- Sacramento29件の研究
- Irvine25件の研究
- Orange25件の研究
- Mountain View21件の研究
- Santa Rosa17件の研究
- Huntington Beach14件の研究
- Concord14件の研究
- Newport Beach14件の研究
- Fullerton13件の研究
- Long Beach12件の研究
- Torrance11件の研究
- Vallejo10件の研究
- Roseville10件の研究
- Glendale9件の研究
- San Bernardino9件の研究
- Anaheim8件の研究
- Westminster8件の研究
- Richmond7件の研究
- Modesto7件の研究
- Fresno7件の研究
- San Jose7件の研究
- Burbank6件の研究
- Fremont6件の研究
- Santa Clara6件の研究
- Oakland6件の研究
- Stockton6件の研究
- Santa Barbara5件の研究
- Oxnard5件の研究
- San Leandro5件の研究
- Berkeley5件の研究
- Sunnyvale5件の研究
- Daly City5件の研究
- Lancaster4件の研究
- San Mateo4件の研究
- Salinas3件の研究
- Santa Maria3件の研究
- Upland3件の研究
- Redwood City3件の研究
- Yuba City3件の研究
- Indio3件の研究
- Riverside3件の研究
- Norwalk3件の研究
- Pleasanton3件の研究
- Clovis3件の研究
公式研究テキスト（英語）
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- City of Hope /ID# 243157, Duarte
- City Of Hope - Seacliff /ID# 263143, Huntington Beach
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144, Irvine
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT04928846A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Start Los Angeles /ID# 284999, Los Angeles
- Valkyrie Clinical Trials /ID# 271322, Los Angeles
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816, Oxnard
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/05更新 · NCT06568939A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- CBCC Global Research, Inc. ( Site 0123), Bakersfield
- Beverly Hills Cancer Center ( Site 0116), Beverly Hills
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT06345729A Study of ZW251 in Participants With Advanced Solid Tumors
- UCSF Comprehensive Cancer Center, San Francisco
- University of California Los Angeles - Cancer Care - Santa Monica (UCLA), Santa Monica
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07164313A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- City of Hope National Medical Center /ID# 277005, Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928, Irvine
- UC San Diego Health - Moores Cancer Center /ID# 278836, La Jolla
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07155187Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Tower Cancer Research Foundation, Beverly Hills
- Cedars-Sinai Medical Center, Los Angeles
- Cedars-Sinai Cancer - Tarzana, Tarzana
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07388524Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Providence - St. Jude Medical Center /ID# 271414, Fullerton
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450, Oxnard
- UCLA - Santa Monica /ID# 271690, Santa Monica
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/05更新 · NCT06772623Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- The Angeles Clinic and Research Institute (Melanoma), Los Angeles
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/05更新 · NCT06060613Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente-Deer Valley Medical Center, Antioch
- Sutter Auburn Faith Hospital, Auburn
- 他56件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- USC / Norris Comprehensive Cancer Center, Los Angeles
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07293247A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- City of Hope National Medical Center, Duarte
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of San Diego Moores Cancer Center, La Jolla
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Providence St. Jude Medical Center ( Site 0106), Fullerton
- VA Long Beach Healthcare System ( Site 0199), Long Beach
- USC Norris Comprehensive Cancer Center ( Site 0205), Los Angeles
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06623422A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Los Angeles Cancer Network, Glendale
- Providence St. Joseph Hospital, Orange
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07365319Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Clinical Research Advisors, LLC, Beverly Hills
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06472245A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Research Site, Santa Rosa
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06996782Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #59, Santa Barbara
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- UC Davis Comprehensive Cancer Center ( Site 3204), Sacramento
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07513376A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- City of Hope, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Tower Cancer Research Foundation, Beverly Hills
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- 他20件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- City of Hope Comprehensive Cancer Center, Duarte
- University of California Los Angeles, Los Angeles
- University of California San Diego Moores Cancer Center, San Diego
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06625775A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- City of Hope National Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- Ronald Reagan UCLA Medical Center, Los Angeles
- 他3件
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07090499Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
- Stanford University, Stanford
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT04585490A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- START LA, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07659782A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Beverly Hills Cancer Center, Beverly Hills
- Orange Coast Memorial Medical Center, Fountain Valley
- Local Institution - 0027, Los Alamitos
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361510A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 9, La Jolla
- ALX Center 11, Santa Monica
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07085091Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Hoag Hospital Newport Beach, Newport Beach
- University of California, Irvine Health, Orange
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Los Angeles
- PHN-012-001 Site, San Diego
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07127874A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Newport Beach
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05877599Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- MemorialCare Long Beach Medical Center, Long Beach
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- University of California at San Diego, La Jolla
- University of California Irvine, Orange
- Stanford Cancer Institute, Stanford
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05498428A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Alta Bates Summit Medical Center Comprehensive Cancer Center, Berkeley
- John Muir Health Clinical Research Center, Concord
- UC San Diego Medical Center - Encinitas, Encinitas
- 他16件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Beverly Hills Cancer Center ( Site 0070), Beverly Hills
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0033), Los Angeles
- Hoag Memorial Hospital Presbyterian ( Site 0096), Newport Beach
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06312137Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130), Burbank
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06170788A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- City of Hope, Duarte
- City of Hope 1, Irvine
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07586202Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- University of California San Diego, La Jolla
- Stanford University, Palo Alto
- UCLA Medical Center, Santa Monica
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Sansum Clinic, Santa Barbara
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/09/25更新 · NCT05920356A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, La Mesa
- Research Site, Los Alamitos
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06868277Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Oncura Health - Anaheim, Anaheim
- Memorial Care Orange Coast Medical Center Attn, Fountain Valley
- MemorialCare Orange Coast Medical Center, Fountain Valley
- 他20件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Moores Cancer Center at UC San Diego Health, La Jolla
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667908ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。